The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
 
Thomas Powles
Honoraria - AstraZeneca; Bristol-Myers Squibb; MERCK; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis/Ipsen; Pfizer; Roche/Genentech
 
Joshua J Meeks
Research Funding - Epizyme
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Hiroyuki Nishiyama
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD
Speakers' Bureau - Chugai Pharma; MSD
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hikmat Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono
 
Ashok Kumar Gupta
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Jiabu Ye
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Sarah E. Donegan
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Dana C. Ghiorghiu
Employment - AstraZeneca; AstraZeneca (I)
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I)
 
Salvatore Ferro
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
James WF Catto
Honoraria - Abbott Laboratories
Speakers' Bureau - ASCO
Travel, Accommodations, Expenses - European Association of Urology